A simple breath test could spot mesothelioma years earlier

NCT ID NCT04106973

Terminated Diagnosis Sponsor: Henry Ford Health System Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study explores whether chemicals in a person's breath, called volatile organic compounds, can serve as early warning signs of pleural mesothelioma in people who have been exposed to asbestos. Researchers will also check if a blood marker, SMRP, adds to the breath test's accuracy. The goal is to find a non-invasive way to catch this cancer at an earlier, more treatable stage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Breath and blood biomarker analysis (volatile organic compounds and SMRP)
What this could lead to: If successful, this could lead to a simple breath test for early detection of mesothelioma in people exposed to asbestos, potentially improving treatment outcomes.
What could go wrong: This is a small early-stage study, so the biomarkers may not prove accurate enough for widespread use. The results will need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASBESTOS EXPOSURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Mesothelioma, Malignant pleural mesothelioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASBESTOS EXPOSURE PLEURAL MESOTHELIOMA PLEURAL PLAQUE

Contacts and locations

Locations

Consultants in Sleep and Pulmonary Medicine

Farmington Hills, Michigan, 48336, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.